The impact of Bacille Calmette-Guérin shortage on immunisation practice and policies in Europe - A Paediatric Tuberculosis Network European Trials Group (ptbnet) survey

详细信息    查看全文

• 作者：Antti Kontturi^a ; ^b ; ^{antti.kontturi@helsinki.fi" class="auth_mail" title="E-mail the corresponding author} ; Begoñ ; a Santiago^c ; ^{bsantiagogarcia@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Marc Tebruegge^d ; ^e ; ^f ; ^{m.tebruegge@soton.ac.uk" class="auth_mail" title="E-mail the corresponding author} ; Ulrich von Both^g ; ^h ; ^{uvb9@gmx.de" class="auth_mail" title="E-mail the corresponding author} ; Eeva Salo^a ; ^{eeva.salo@hus.fi" class="auth_mail" title="E-mail the corresponding author} ; Nicole Ritz^f ; ⁱ ; ^{nicole.ritz@unibas.ch" class="auth_mail" title="E-mail the corresponding author} ; Ptbnet BCG shortage project collaborators ; on behalf of the Paediatric Tuberculosis Network European Trials Group (ptbnet)Daniel Blá ; zquez ; Matthias Bogyi ; Danilo Buonsenso ; Alexandra Dreesman ; Uros Krivec ; Franç ; oise Mouchet ; Sahar Nejat ; Olaf Neth ; Ivan Pavić ; Ezia Ruga ; Rupert Schlags ; Antoni Soriano-Arandes ; Steffi Thee ; Maria Tsolia ; Svetlana Velizarova ; on behalf of the Paediatric Tuberculosis Network European Trials Group (ptbnet)
• 关键词：Tuberculosis ; TB ; BCG ; Supply ; Public health ; Vaccine
• 刊名：Tuberculosis
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：101
• 期：Complete
• 页码：125-129
• 全文大小：226 K

文摘

Recent reports indicate an ongoing BCG shortage that may influence immunisation practice. This study aimed to determine current availability of BCG vaccine across Europe, and implications on immunisation practices and policies in Europe.

Methods

Web-based survey among Paediatric Tuberculosis Network European Trials Group (ptbnet) members, between May and October 2015.

Results

Twenty individuals from 13 European countries participated. Ongoing shortages were reported in eight countries routinely using BCG (8/11, 73%). As a consequence of the shortage, BCG was not given as completely unavailable in some countries (2/8, 25%), was given only whenever available (1/8, 13%), or only in certain regions of the country (1/8, 13%). Strategies reported to reduce loss of immunisation were administration to selected high-risk individuals (2/8, 25%), or cohorting vaccinees on specific days to maximise the use of multi-dose vials (3/8, 38%). Authorities in two countries each were considering a change of manufacturer/supplier (2/8, 25%).

Conclusions

The BCG shortage in Europe leads to significant changes in immunisation policies including changes of BCG vaccine strain and manufacturer. In addition, infants and children eligible for immunisation are at risk of not receiving BCG. To ensure necessary BCG immunisations, collaboration between national health agencies and vaccine manufacturers is crucial.